ÂÜÀòÂÒÂ×

Dr. Eran Ophir joined Compugen in 2015 and was appointed SVP of Research and Drug Discovery in March 2020. In his role, Dr. Ophir is responsible for the Company’s Research and Drug Discovery activities, overseeing the research into the biology of the Company’s computationally discovered targets and therapeutic lead identification and selection. Dr. Ophir brings to Compugen significant expertise in immunology and immuno-oncology from his research work at the Weizmann Institute of Science and post-doctoral fellowship at the Ludwig Institute for Cancer Research in Lausanne, Switzerland. Dr. Ophir joined Compugen’s immuno-oncology group as a senior scientist and has since held various positions in the Research and Development department, with increasing responsibilities. Dr. Ophir received a B.Sc. in Bioinformatics from Tel Aviv University and a Ph.D. in Biology from the Weizmann Institute of Science.